Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Smoothened homolog (SMO) is a transmembrane protein that functions as a G protein-coupled receptor (GPCR) in the Frizzled family. It is a key signal transducer in the Hedgehog (Hh) signaling pathway, crucial for embryonic development and tissue homeostasis. Mutations in SMO are implicated in cancer and drug resistance. SMO is a target of several small molecule inhibitors like vismodegib.
SMO transduces Hedgehog signaling by relieving the inhibition of Patched (PTCH) on SMO. Drugs modulate SMO's heptahelical bundle conformation to promote or inhibit downstream signaling activity. Agonists activate SMO, while antagonists like vismodegib inhibit SMO activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Smoothened homolog (SMO).